Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STTK Stock Forecast 2026-2027
$7.53
Current Price
$719.18M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STTK Price Targets
+139.0%
To High Target of $18.00
+112.5%
To Median Target of $16.00
+32.8%
To Low Target of $10.00
STTK Price Momentum
+13.4%
1 Week Change
+52.1%
1 Month Change
+829.6%
1 Year Change
+106.3%
Year-to-Date Change
-9.6%
From 52W High of $8.33
+957.6%
From 52W Low of $0.71
📊 TOP ANALYST CALLS
Did STTK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Shattuck Labs is one of their latest high-conviction picks.
Latest STTK Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, STTK has a bullish consensus with a median price target of $16.00 (ranging from $10.00 to $18.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $7.53, the median forecast implies a 112.5% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yigal Nochomovitz at Citigroup, projecting a 139.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STTK Analyst Ratings
8
Buy
0
Hold
0
Sell
STTK Price Target Range
Low
$10.00
Average
$16.00
High
$18.00
Current: $7.53
Latest STTK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STTK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 9, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $18.00 |
| Jun 8, 2026 | Needham | Joseph Stringer | Buy | Maintains | $17.00 |
| Jun 8, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $18.00 |
| Jun 5, 2026 | Citigroup | Yigal Nochomovitz | Buy | Upgrade | $7.00 |
| May 8, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 27, 2026 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Apr 20, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 13, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Mar 6, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 28, 2026 | Piper Sandler | Overweight | Initiates | $N/A | |
| Jan 6, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Dec 1, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Sep 8, 2025 | Wedbush | Outperform | Initiates | $N/A | |
| Aug 14, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Aug 14, 2025 | Needham | Hold | Reiterates | $N/A | |
| Mar 27, 2025 | Needham | Hold | Reiterates | $N/A | |
| Mar 27, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 17, 2025 | Leerink Partners | Outperform | Initiates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 14, 2024 | Needham | Hold | Reiterates | $N/A |
Shattuck Labs Inc. (STTK) Competitors
The following stocks are similar to Shattuck Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Shattuck Labs Inc. (STTK) Financial Data
Shattuck Labs Inc. has a market capitalization of $719.18M with a P/E ratio of -10.8x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -5,258.3% and return on equity of -61.0%.
Valuation Metrics
Market Cap
$719.18M
Enterprise Value
$431.60M
P/E Ratio
-10.8x
PEG Ratio
0.2x
Price/Sales
675.2x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-5,258.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.7%
Current Ratio
22.1x
Debt/Equity
3.0x
ROE
-61.0%
ROA
-36.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Shattuck Labs Inc. (STTK) Business Model
About Shattuck Labs Inc.
What They Do
Develops novel biologic therapies for cancer.
Business Model
Shattuck Labs Inc. utilizes its proprietary Agonist Redirected Checkpoint (ARC) platform to create therapies that enhance the immune system's ability to combat cancer and autoimmune diseases. The company generates revenue through the development of its clinical-stage pipeline, which includes several candidates targeting different cancer types, and through strategic partnerships and collaborations that help advance its research and development efforts.
Additional Information
The company is positioned within the biotechnology sector and focuses on innovative immunotherapy approaches, aiming to provide superior treatment options compared to existing therapies. Its emphasis on dual engagement of T cells and antigen-presenting cells is designed to improve therapeutic efficacy and minimize side effects.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Dr. Taylor H. Schreiber M.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.shattucklabs.comShattuck Labs Inc. (STTK) Latest News & Analysis
Latest News
Quick Summary
Shattuck Labs Inc. (NASDAQ:STTK) shares declined on Monday after news related to its lead drug candidate, SL-325.
Why It Matters
Shattuck Labs' stock decline signals potential issues with SL-325, impacting investor confidence and future financial performance. This could affect market perception and valuation.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Shattuck Labs, Inc. (STTK) reported on Phase I results for its DR3 blocking antibody SL-325 and provided an update on its pipeline developments.
Why It Matters
Positive Phase I results for SL-325 could indicate potential market success, impacting Shattuck Labs' valuation and attractiveness to investors in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Shattuck Labs (NASDAQ: STTK) reported Phase 1 trial data for its lead DR3 blocking antibody candidate SL-325, aimed at treating inflammatory and immune-mediated diseases.
Why It Matters
The announcement of Phase 1 trial data for SL-325 signals progress in Shattuck Labs' drug development, potentially impacting stock performance and investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
1 month ago
Quick Summary
Shattuck Labs (NASDAQ: STTK) has received notices to exercise about 50.6 million common stock warrants, representing 96% of those issued in its August 2025 private placement.
Why It Matters
Shattuck Labs' significant warrant exercise indicates strong investor confidence and potential capital influx, which could enhance R&D efforts and drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Shattuck Labs (NASDAQ: STTK) has launched a public offering of common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15%.
Why It Matters
Shattuck Labs' public offering could dilute existing shares, impacting stock value. The success of its drug development also influences future growth prospects, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Shattuck Labs, Inc. (NASDAQ: STTK) has priced a public offering of 10.88 million shares at $4.00 each, raising about $75 million. The offering closes on June 11, 2026, pending conditions.
Why It Matters
Shattuck Labs' $75 million capital raise can enhance its development pipeline and liquidity, potentially driving future growth and impacting stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About STTK Stock
What is Shattuck Labs Inc.'s (STTK) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Shattuck Labs Inc. (STTK) has a median price target of $16.00. The highest price target is $18.00 and the lowest is $10.00.
Is STTK stock a good investment in 2027?
According to current analyst ratings, STTK has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STTK stock?
Wall Street analysts predict STTK stock could reach $16.00 in the next 12 months. This represents a 112.5% increase from the current price of $7.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Shattuck Labs Inc.'s business model?
Shattuck Labs Inc. utilizes its proprietary Agonist Redirected Checkpoint (ARC) platform to create therapies that enhance the immune system's ability to combat cancer and autoimmune diseases. The company generates revenue through the development of its clinical-stage pipeline, which includes several candidates targeting different cancer types, and through strategic partnerships and collaborations that help advance its research and development efforts.
What is the highest forecasted price for STTK Shattuck Labs Inc.?
The highest price target for STTK is $18.00 from Yigal Nochomovitz at Citigroup, which represents a 139.0% increase from the current price of $7.53.
What is the lowest forecasted price for STTK Shattuck Labs Inc.?
The lowest price target for STTK is $10.00 from at , which represents a 32.8% increase from the current price of $7.53.
What is the overall STTK consensus from analysts for Shattuck Labs Inc.?
The overall analyst consensus for STTK is bullish. Out of 4 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are STTK stock price projections?
Stock price projections, including those for Shattuck Labs Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 5:23 AM UTC